button bars forest bayes pooled summary circles
 
deaths (OS)progression or deaths (PFS)RFS/DFS

metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA) metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA)

versus placebo
pembrolizumab alone vs. placebo 1 -300 [-573; -26] /10000
18/496 vs. 33/498		-NaN [NaN; NaN] /10000
0/0 vs. 0/0

metastatic/advanced RCC (mRCC) - 1st line (L1) metastatic/advanced RCC (mRCC) - 1st line (L1)

versus sunitinib
atezolizumab alone vs. sunitinib 1 -81 [-1270; 1432] /10000
61/103 vs. 59/101		-
atezolizumab plus bevacizumab vs. sunitinib 2 108 [-532; 748] /10000
194/454 vs. 192/461		792 [-540; 2124] /10000
67/101 vs. 59/101		-
avelumab plus axitinib vs. sunitinib 1 -439 [-1022; 144] /10000
109/442 vs. 129/444		-792 [-1445; -140] /10000
180/442 vs. 216/444		-
nivolumab plus cabozantinib vs. sunitinib 1 NaN [NaN; NaN] /10000
0/0 vs. 0/0		NaN [NaN; NaN] /10000
0/0 vs. 0/0		-
nivolumab plus ipilimumab vs. sunitinib 3 1005 [483; 1528] /10000
429/550 vs. 371/546		NaN [NaN; NaN] /10000
0/0 vs. 0/0		-
pembrolizumab plus axitinib vs. sunitinib 1 NaN [NaN; NaN] /10000
0/0 vs. 0/0		NaN [NaN; NaN] /10000
0/0 vs. 0/0		-
pembrolizumab plus lenvatinib vs. sunitinib 1 NaN [NaN; NaN] /10000
0/0 vs. 0/0		-1235 [-1964; -507] /10000
160/355 vs. 205/357		-

mRCC - L1 - PDL1 negative metastatic/advanced RCC (mRCC) - 1st line (L1) mRCC - L1 - PDL1 negative

versus sunitinib
atezolizumab plus bevacizumab vs. sunitinib 1 -NaN [NaN; NaN] /10000
0/0 vs. 0/0		-

mRCC - L1 - PDL1 positive metastatic/advanced RCC (mRCC) - 1st line (L1) mRCC - L1 - PDL1 positive

versus sunitinib
atezolizumab alone vs. sunitinib 1 --907 [-2669; 854] /10000
32/54 vs. 41/60		-
atezolizumab plus bevacizumab vs. sunitinib 2 NaN [NaN; NaN] /10000
0/0 vs. 0/0		NaN [NaN; NaN] /10000
0/0 vs. 0/0		-
avelumab plus axitinib vs. sunitinib 1 -280 [-1004; 445] /10000
66/270 vs. 79/290		-1000 [-1820; -180] /10000
108/270 vs. 145/290		-

metastatic/advanced RCC (mRCC) - 2nd line (L2) metastatic/advanced RCC (mRCC) - 2nd line (L2)

versus everolimus
nivolumab alone vs. everolimus 1 -768 [-1449; -86] /10000
183/410 vs. 215/411		-78 [-646; 489] /10000
318/410 vs. 322/411		-

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons